Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736565 · ClinicalTrials.gov registry record · Phase 1
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
A Phase 1 study, sponsored by Gradalis.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02736565: Completed Phase 1 study, sponsored by Gradalis.
NCT02736565 is a Phase 1 study that has completed, run by Gradalis. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02736565, a Phase 1 study, has completed, sponsored by Gradalis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
Primary Outcome
Adverse events(AEs) will be recorded for the duration of the participant's study treatment (following the first dose of the investigational product), and for up to 60 days following the last study treatment. AEs will be graded and reported using the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03. The relationship of each event to the investigational product will be assessed by the Treating Physician.
Interventions
- BIOLOGICAL pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-08-04 |
| Phase | Phase 1 |
What the finished NCT02736565 record still lists
NCT02736565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex is the first listed.
NCT02736565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02736565 about?
NCT02736565 is a clinical study titled "Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma". The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
What is the current status of trial NCT02736565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-10. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT02736565?
The interventions under investigation include: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex (BIOLOGICAL).
Who is sponsoring clinical trial NCT02736565?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02736565's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia